Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients positive for COVID-19 by polymerase chain reaction (PCR) assay or alternative accepted methodology~2. PENN class 2,3,4 CRS~3. Respiratory insufficiency with supplemental oxygen to maintain O2 sat greater than 89%~4. Clinically positive imaging by chest x-ray (CXR) or CT scan with evidence of bilateral pulmonary infiltrates, ground glass opacification or other pattern of consolidation felt likely to be linked to COVID infection or complication thereof~5. Age 12-80 years of age~Exclusion Criteria:~1. Pregnancy~2. Breast feeding~3. Class 3-4 New York Heart Association (NYHA) heart failure~4. Current use of synthetic disease modifying anti-rheumatic drugs (DMARDS) or IL-6 inhibitors or other immunosuppressive therapies outside of number five below~5. Current use of chronic corticosteroids if in excess of prednisone 10mg per day or equivalent~6. Suspected or confirmed clinically significant bacterial infection~7. History of tuberculosis (TB)~8. History of HIV~9. History of irritable bowel disease (IBD)~10. JAK inhibitor use within last 30 days~11. Creatinine clearance less than 15 ml / min~12. Absolute neutrophil count \< 1000~13. Platelet count \< 50,000~14. Clinical assessment that the trial could pose unacceptable risk by study participation~15. Current enrollment on another investigational protocol for COVID-19 induced CRS~16. Stage 4 obstructive lung disease with chronic hypoxic respiratory failure requiring supplemental O2 at baseline, or interstitial lung disease (ILD) with chronic hypoxic respiratory failure requiring supplemental O2 at baseline

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 - TPE Alone (Type: EXPERIMENTAL): TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or fresh frozen plasma (FFP) replacement if underlying coagulopathy
- 2 - TPE Plus Ruxolitinib (Type: EXPERIMENTAL): TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or fresh frozen plasma (FFP) replacement if underlying coagulopathy combined with ruxolitinib 5mg po twice daily (BID) beginning day prior to first TPE and continuing BID for total of 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).